By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors PICAUD, Serge; SAHEL, Jose Alain; FIRAS, Jammoul; CORIAT, Caroline; SIMONUTTI, Manuel, filed on February 23, 2016, was made available online on July 14, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent
Before we look forward to the FDA activity of August, the following are some noteworthy developments that occurred on the U.S. regulatory front in July. Shire' s Xiidra passed the FDA muster on its second try on July 11, 2016, becoming the first prescription eye drop for the treatment of both signs and symptoms of dry eye disease in adult patients.
July 29 The front lines of a high-stakes battle over prescription drugs crossed Vickie Goldstein's 100- pound body in Delray Beach. Florida's Medicaid system was telling her she had to get sicker with liver scarring that could push her to the brink of a transplant before it would approve prescription medicine with a 90 percent or better chanc
According to news reporting originating from Shanghai, People's Republic of China, by NewsRx correspondents, research stated, "Drug discovery and development is vital to the well-being of mankind and sustainability of the pharmaceutical industry. For more information on this research see: Application of chemical biology in target identification and
Findings on Translational Medicine Reported by Researchers at Sloan School of Management. According to news reporting from Cambridge, Massachusetts, by NewsRx journalists, research stated, "A crisis is building over the prices of new transformative therapies for cancer, hepatitis C virus infection, and rare diseases. The news correspondents obtaine
By a News Reporter-Staff News Editor at Drug Week Galderma, a global leader focused on medical solutions in skin health, announced that its U.S. affiliate, Galderma Laboratories, L.P. received approval from the U.S. Food and Drug Administration for Differin Gel as an over-the-counter treatment for acne. It also marks the first new, FDA- approved
By a News Reporter-Staff News Editor at Health& Medicine Week InVivo Therapeutics Holdings Corp. today provided an update on the INSPIRE study of the Neuro-Spinal Scaffold?. The implantation was performed by Vidant Medical Group neurosurgeons Stuart Lee, M.D., the Principal Investigator at the site, and Hilal Kanaan, M.D., approximately 40 hour
By a News Reporter-Staff News Editor at Drug Week Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed public offering of American Depositary Shares.
By a News Reporter-Staff News Editor at Drug Week Novocure announced that the U.S. Food and Drug Administration approved its premarket approval supplement application for Novocure's second generation Optune system. Novocure started offering the second generation Optune system to patients in Germany in October 2015 and has since made it available
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by the inventors LIU, Hong; XIE, Xin; SUN, Haifeng; LI, Jing; ZHAO, Fei; CHEN, Ying; LI, Zeng; ZHOU, Yu; JIANG, Hualiang; CHEN, Kaixian, filed on May 4, 2014, was made available online on Jul
By a News Reporter-Staff News Editor at Drug Week CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY CO., LTD. has been issued patent number 9388184, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. This patent was filed on April 30, 2010 and was published online on July 12, 2016. From the background information supplie
By a News Reporter-Staff News Editor at Drug Week A patent by the inventors Samson, C. Michael; Liang, Bo; Capriotti, Joseph A., filed on June 26, 2014, was published online on July 12, 2016, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. Patent number 9387223 is assigned to CLS Pharmaceuticals, Inc..
By a News Reporter-Staff News Editor at Drug Week ADARE PHARMACEUTICALS, INC. has been issued patent number 9387167, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventors are Perrett, Stephen; Cohen, Fredric Jay; Venkatesh, Gopi. This patent was filed on June 23, 2014 and was published onli
By a News Reporter-Staff News Editor at Drug Week A patent by the inventors Hansen, Henrik Bjork; Grunnet, Morten; Bentzen, Bo Hjorth; Hyveled-Nielsen, Lars; Lassen, Jorgen Buus; Sundgreen, Claus, filed on November 10, 2015, was published online on July 12, 2016, according to news reporting originating from Alexandria, Virginia, by NewsRx corresp
Reports from University of Texas Advance Knowledge in Pharmaceutical Research. For more information on this research see: Challenges and Strategies in Thermal Processing of Amorphous Solid Dispersions: A Review. Aaps Pharmscitech, 2016; 17: 43-55. Aaps Pharmscitech can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. Our news
Studies Conducted at Bristol-Myers Squibb on Immunoglobulins Recently Reported. According to news reporting originating from Princeton, New Jersey, by NewsRx correspondents, research stated, "Antibody-drug conjugates are emerging modalities in the pharmaceutical industry. Our news editors obtained a quote from the research from Bristol-Myers Squibb
AbbVie, a global biopharmaceutical company, today announced the initiation of a Phase 3 clinical trial to study the safety and efficacy of venetoclax in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma who are considered sensitive or nave to proteasome inhibitors and have received one to thr
AcelRx Pharmaceuticals, Inc.,, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a corporate update and reported financial results for the three and six months ended June 30, 2016. Pending successful results of the SAP302 and SAP303 studies,
New Initiative Provides Access to Scientific Advice and Supports Accelerated Assessment for Therapies Targeting Unmet Medical Needs PHILADELPHIA, Pa. and OXFORD, UK, July 28, 2016 Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that the European Medicines Agency has granted access to its newly-established
PHILADELPHIA, Pa. and OXFORD, UK, 2016-07-28 17:27 CEST Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that the European Medicines Agency has granted access to its newly-established Priority Medicines regulatory initiative for the company s SPEAR T-cell therapy targeting NY-ESO for the treatment of
Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc., announced today that the European Commission has designated volanesorsen as an orphan medicinal product for the treatment of familial partial lipodystrophy. The EC's approval follows a positive opinion in June from the European Medicine Agency's Committee for Orphan...
On July 28, 2016, Alexion Pharmaceuticals, Inc. issued a press release relating to its results of operations and financial conditions for the quarter ended June 30, 2016. 99.1 Press Release issued by Alexion Pharmaceuticals, Inc. on July 28, 2016 relating to its results of operations and financial conditions for the quarter ended June 30, 2016.
Alkermes plc today reported financial results for the second quarter of 2016.. We are also encouraged by our progress with the launch of ARISTADA, for which our second quarter results were slightly ahead of expectations, commented James Frates, Chief Financial Officer of Alkermes. Today we are improving our financial expectations for 2016 to
Delegates at last week's international AIDS conference protested drug manufacturer Gilead Sciences, over the price of its extremely effective hepatitis C medication, sofosbuvir. In the United States the cost of sofosbuvir is $84,000. It would therefore cost approximately R13, 500 in South Africa.
ANGLE plc, the specialist medtech company, today announces audited preliminary results for the year ended 30 April 2016. Sales pipeline developing in the research use market Analytical and clinical study programmes developed to progress FDA clearance for Parsortix planned initial FDA clearance in metastatic breast cancer three world-leading US canc